- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00372632
IPT of Malaria With SP in Different Zones of Drug Resistance in Rwanda
Intermittent Preventive Treatment of Malaria With Sulfadoxine-Pyrimethamine in Different Zones of Drug Resistance in Rwanda
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
The present study will address the question whether the use of IPT using SP in pregnancy is efficacious in Rwanda, where it is going to be used for the first time, in areas with high levels of SP resistance. While the implementation of the new policy will take place in areas at low SP resistance level, where we expect pregnant women and newborns to benefit from it, it is of paramount importance to clarify which is the real impact of IPT/SPin areas of high SP drug resistance and at what level of SP resistance this strategy is still efficacious. As bed nets are a part of the actual control strategy of malaria in pregnancy all women will receive a bed net at enrolment.
This will be a randomized blinded placebo controlled trial: women in the 16-28th week of gestation will be offered enrolment into the study and randomized to receive IPT/SP regimen or placebo once during the second and once in the third trimesters.
The study will be conducted in Mashesha (estimated SP drug resistance 20%, 12% in 2000), Kicukiro (40% SP resistance) and Rukara (60% SP resistance). In each of these sites there are about 1000 deliveries per year. According to DHMT data, over 75% of pregnant women attend antenatal clinics, usually booking between 15 and 25 weeks of gestation. Based on this study we expect to find placental malaria prevalence over 50% in all sites.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 4
Kontakte und Standorte
Studienorte
-
-
-
Kigali, Ruanda
- Programme Nationale de Controle de Paludisms
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
- Pregnant women between 16-28 weeks of gestation;
- Residence within the catchment's area of the health facility;
- Willing to deliver at the health facility;
- Willing to ; adhere to all requirements of the study;
- Willing to provide written informed consent;
- Aged 21 years and above
Exclusion Criteria:
- Severe anemia (Hb < 6 g/dL)
- History of allergic reactions to sulfa drugs;
- Taking other sulfa drugs as CTX;
- History of known pregnancy complications (e.g. breech presentation, severe pre-eclampsia, prior caesarian section);
- History or presence of major illnesses likely to influence pregnancy outcome including diabetes mellitus, severe renal or heart disease, or active tuberculosis, prior to randomization;
- Any significant illness that requires hospitalization;
- Intent to move out of the study catchment's area before delivery or deliver at relative's home out of the catchment's area;
- Prior enrollment in the study or concurrent enrollment in another study
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Vervierfachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Placebo-Komparator: Placebo
|
The control group receives placebo similar in taste and appearance to to the experimental arm
|
Experimental: sulfadoxine-pyrimethamine
|
The intervention group receives 1500mg of sulfadoxine and 75mg of pyrimethamine at enrollment and in the third trimester.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
malaria infection will be defined as the presence of asexual stage parasites on thick smears made with maternal side placental blood and Maternal peripheral blood
Zeitfenster: maternal placental blood at delivery; maternal peripheral blood at monthly visits between 16 weeks of gestation and delivery
|
maternal placental blood at delivery; maternal peripheral blood at monthly visits between 16 weeks of gestation and delivery
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
LBW = birth weight <2,500 grams
Zeitfenster: at delivery
|
at delivery
|
Premature delivery = delivery prior to 37 weeks gestation
Zeitfenster: at delivery
|
at delivery
|
Spontaneous miscarriage = any spontaneous abortion before the end of gestation
Zeitfenster: at delivery
|
at delivery
|
Stillbirth
Zeitfenster: at delivery
|
at delivery
|
Cord blood parasitaemia = presence of asexual stage parasites in thick smears
Zeitfenster: at delivery
|
at delivery
|
Neonatal death = infant death within the first 28 days of life
Zeitfenster: 7days and 6 weeks after delivery
|
7days and 6 weeks after delivery
|
Maternal anemia = Hb <11.0 g/dL
Zeitfenster: at monthly visits between 16 weeks of gestation and delivery
|
at monthly visits between 16 weeks of gestation and delivery
|
Maternal severe anemia = Hb <6 g/dL
Zeitfenster: at monthly visits between 16 weeks of gestation and delivery
|
at monthly visits between 16 weeks of gestation and delivery
|
Symptomatic maternal malaria infection = axillary temperature 37.5°C and asexual parasitaemia
Zeitfenster: at monthly visits between 16 weeks of gestation and delivery
|
at monthly visits between 16 weeks of gestation and delivery
|
Severe maternal adverse reactions to SP = severe cutaneous reactions (e.g., erythema multiform, Stevens-Johnson syndrome, or toxic epidermal necrolysis)
Zeitfenster: at monthly visits between 16 weeks of gestation and delivery plus at day 7 and week 6 after delivery
|
at monthly visits between 16 weeks of gestation and delivery plus at day 7 and week 6 after delivery
|
Mitarbeiter und Ermittler
Ermittler
- Studienleiter: Umberto D'Alessandro, MD,MSc, PHD, Institute of Tropical Medicine Antwerp
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Infektionen
- Vektor-übertragene Krankheiten
- Parasitäre Krankheiten
- Protozoen-Infektionen
- Malaria
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antiinfektiva
- Enzym-Inhibitoren
- Antiprotozoenmittel
- Antiparasitäre Mittel
- Antimalariamittel
- Folsäure-Antagonisten
- Antiinfektiva, Urin
- Renale Agenten
- Pyrimethamin
- Sulfadoxin
- Fanasil, Pyrimethamin-Medikamentenkombination
Andere Studien-ID-Nummern
- 05 34 5 520
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Non HIV Infected Pregnant Women
-
Azienda Socio Sanitaria Territoriale degli Spedali...AbgeschlossenHIV-Infektionen | HIV-bedingtes LymphomItalien
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)ZurückgezogenHIV infektion | Rezidivierendes Hodgkin-Lymphom | Rezidivierendes Non-Hodgkin-Lymphom | AIDS-bedingtes Non-Hodgkin-Lymphom | AIDS-bezogenes Hodgkin-LymphomVereinigte Staaten
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Noch keine RekrutierungLymphom | Lymphom, Non-Hodgkin | Non-Hodgkin-Lymphom | Non-Hodgkin-Lymphom | Refraktäres B-Zell-Non-Hodgkin-Lymphom | Refraktäres Non-Hodgkin-Lymphom | Hochgradiges B-Zell-Lymphom | ZNS-Lymphom | Lymphome Non-Hodgkin-B-Zelle | Rezidiviertes Non-Hodgkin-Lymphom | Lymphom, Non-Hodgkins | Großes B-Zell-Lymphom | Lymphom, Non-Hodgkin, Erwachsener und andere Bedingungen
-
ANRS, Emerging Infectious DiseasesUniversity Hospital, Grenoble; Hopital Antoine Beclere; Dr Yassine Taoufik Dr... und andere MitarbeiterAbgeschlossen
-
Rotkreuzklinikum München gGmbHRekrutierungAIDS-bezogenes Lymphom | HIV-bezogenes LymphomDeutschland, Spanien, Vereinigtes Königreich, Niederlande
-
National Institute of Allergy and Infectious Diseases...Schering-PloughAbgeschlossenHIV-Infektionen | Lymphom, Non-HodgkinVereinigte Staaten
-
French National Agency for Research on AIDS and...BeendetHIV-Infektionen | Lymphom, Non-HodgkinFrankreich
-
RibozyomeAbgeschlossenHIV-Infektionen | Lymphom, Non-HodgkinVereinigte Staaten
-
National Institute of Allergy and Infectious Diseases...AbgeschlossenHIV-Infektionen | Lymphom, Non-HodgkinVereinigte Staaten
-
Andres J. M. FerreriAbgeschlossenHIV | Burkitt-LymphomItalien
Klinische Studien zur placebo
-
SamA Pharmaceutical Co., LtdUnbekanntAkute Bronchitis | Akute Infektion der oberen AtemwegeKorea, Republik von
-
National Institute on Drug Abuse (NIDA)AbgeschlossenCannabiskonsumVereinigte Staaten
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyAbgeschlossenMännliche Probanden mit Typ-II-Diabetes (T2DM)Deutschland
-
Instituto de Investigación Hospital Universitario...Creaciones Aromáticas Industriales, S.A. (CARINSA)Abgeschlossen
-
Soroka University Medical CenterAbgeschlossen
-
Regado Biosciences, Inc.AbgeschlossenGesunder FreiwilligerVereinigte Staaten
-
Texas A&M UniversityNutraboltAbgeschlossenGlucose and Insulin Response
-
Longeveron Inc.BeendetHypoplastisches LinksherzsyndromVereinigte Staaten
-
Heptares Therapeutics LimitedAbgeschlossenPharmakokinetik | SicherheitsproblemeVereinigtes Königreich